Travere Therapeutics Inc TVTX:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:01 PM EST
26.34UNCH (UNCH)
Volume
90,500
Close
26.34quote price arrow down-1.06 (-3.87%)
Volume
722,235
52 week range
8.98 - 33.09

...

Loading . . .

KEY STATS

  • Open26.80
  • Day High27.82
  • Day Low25.77
  • Prev Close27.40
  • 52 Week High33.09
  • 52 Week High Date02/02/21
  • 52 Week Low8.98
  • 52 Week Low Date03/18/20
  • Market Cap1.587B
  • Shares Out60.24M
  • 10 Day Average Volume0.60M
  • Dividend-
  • Dividend Yield-
  • Beta0.76
  • 1 Year % Change66.71

RATIOS/PROFITABILITY

  • EPS (TTM)-3.82
  • P/E (TTM)-6.89
  • Fwd P/E (NTM)-17.32
  • EBITDA (MRQ)-50.798M
  • ROE (MRQ)-87.32%
  • Revenue (MRQ)198.32M
  • Gross Margin (MRQ)96.91%
  • Net Margin (MRQ)-95.19%
  • Debt To Equity (MRQ)101.95%

EVENTS

  • Earnings Date05/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Travere Therapeutics Inc News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Travere Therapeutics Inc., formerly Retrophin Inc., is a biopharmaceutical company. The Company specializing in identifying, developing and delivering therapies to people living with rare disease. It's pipeline includes sparsentan (RE-021), a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). Sparsentan is an investigational product candidate with a dual mechanism of action, selective endothelin receptor...
Gary Lyons
Chairman
Eric Dube Ph.D.
President
Laura Clague CPA
Chief Financial Officer
Address
3611 Valley Centre Dr, Suite 300
San Diego, CA
92130-3330
United States